Treatment of Late Abortion: Evacuatio Uteri or Conservative Treatment

Overview[ - collapse ][ - ]

Purpose A randomize trial: expectation or evacuatio uteri for the treatment after late abortion
ConditionAbortion, Spontaneous
Abortion, Induced
InterventionDrug: Cytotec
PhasePhase 4
SponsorRigshospitalet, Denmark
Responsible PartyRigshospitalet, Denmark
ClinicalTrials.gov IdentifierNCT00256009
First ReceivedNovember 18, 2005
Last UpdatedMay 31, 2006
Last verifiedNovember 2005

Tracking Information[ + expand ][ + ]

First Received DateNovember 18, 2005
Last Updated DateMay 31, 2006
Start DateNot Provided
Estimated Primary Completion DateJanuary 2009
Current Primary Outcome Measures
  • Side-effect
  • Complication
Current Secondary Outcome MeasuresQuality of life

Descriptive Information[ + expand ][ + ]

Brief TitleTreatment of Late Abortion: Evacuatio Uteri or Conservative Treatment
Official TitleEvacuatio Uteri or Conservtive Treatment After Late Abortion. A Randomize Trial.
Brief Summary
A randomize trial: expectation or evacuatio uteri for the treatment after late abortion
Detailed Description
A randomize trial adressing 200 women consecutively recruited from clinical practice at
Rigshospitalet.Expectation: administration of 800 microgram Cytotec half an hour after
delivery. Surgery: Evacuation of the uterus
Study TypeInterventional
Study PhasePhase 4
Study DesignAllocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Condition
  • Abortion, Spontaneous
  • Abortion, Induced
InterventionDrug: Cytotec
Study Arm (s)Not Provided

Recruitment Information[ + expand ][ + ]

Recruitment StatusNot yet recruiting
Estimated Enrollment200
Estimated Completion DateJanuary 2009
Estimated Primary Completion DateNot Provided
Eligibility Criteria
Inclusion Criteria:

abortion at gestational age (ultrasound) 14+0 - 20+0

Exclusion Criteria:

Allergy to cytotec
GenderFemale
Ages18 Years
Accepts Healthy VolunteersNo
ContactsContact: Lars Alling Møller, Md phd
0045 35451338
Lars.Alling@rh.dk
Location CountriesNot Provided

Administrative Information[ + expand ][ + ]

NCT Number NCT00256009
Other Study ID NumbersKF 01 279545
Has Data Monitoring CommitteeNot Provided
Information Provided ByRigshospitalet, Denmark
Study SponsorRigshospitalet, Denmark
CollaboratorsNot Provided
Investigators Principal Investigator: Lars Alling Møller, MD phd Rigshospitalet, Denmark
Verification DateNovember 2005